含脂质体多柔比星超载方案一线治疗晚期弥漫大B细胞淋巴瘤或经典型霍奇金淋巴瘤患者的初步结果:一项单中心II期研究
这项单中心II期研究(2016-2021年)纳入81例晚期弥漫大B细胞淋巴瘤(n=53)或经典型霍奇金淋巴瘤(n=28)成人患者,接受含脂质体多柔比星超载方案(R-COMP-DI或MBVD-DI)一线治疗。中期FDG-PET中72/81例Deauville评分≤3,治疗结束时90%患者达完全缓解,中位随访21个月无进展生存率为77.3%(95%CI 68%-88%)。
要点
- 81例晚期DLBCL或c-HL患者接受含脂质体多柔比星超载方案一线治疗,中位随访21个月PFS为77.3%。
- 20例发生≥3级不良事件,其中4例需住院治疗。
核心结论
- 含脂质体多柔比星超载方案在高危DLBCL/c-HL中可能是一种有前景的策略,值得在III期试验中验证,以提高中期FDG-PET阴性病例的发生率。
研究设计与样本
- 单中心II期研究(2016-2021年),纳入81例晚期DLBCL(n=53)和c-HL(n=28)成人患者。
- DLBCL患者接受R-COMP-DI方案:脂质体多柔比星70 mg/m2联合标准利妥昔单抗、环磷酰胺、长春新碱和泼尼松共3周期,随后3周期脂质体多柔比星减至50 mg/m2。
- c-HL患者接受MBVD-DI方案:脂质体多柔比星35 mg/m2联合标准博来霉素、长春花碱和达卡巴嗪共2周期,随后4周期脂质体多柔比星减至25 mg/m2。
主要发现
- R-COMP-DI和MBVD-DI的中位剂量强度分别为91%和94%。
- 中期FDG-PET中72/81例Deauville评分≤3(1例因早期死亡未行中期FDG-PET)。
- 治疗结束时90%患者达完全缓解。
- 20例发生≥3级不良事件,其中4例需住院治疗。
- 中位随访21个月,全人群无进展生存率为77.3%(95%CI 68%-88%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the impact of liposomal doxorubicin (NPLD) supercharge-containing therapy on interim fluorodeoxyglucose positron emission tomography (interim-FDG-PET) responses in high-risk diffuse large B-cell lymphoma (DLBCL) or classical Hodgkin lymphoma (c-HL). In this phase II study (2016-2021), 81 adult patients with advanced-stage DLBCL (n = 53) and c-HL (n = 28) received front-line treatment with R-COMP-dose-intensified (DI) and MBVD-DI. R-COMP-DI consisted of 70 mg/m2 of NPLD plus standard rituximab, cyclophosphamide, vincristine and prednisone for three cycles (followed by three cycles with NPLD de-escalated at 50 mg/m2 ); MBVD-DI consisted of 35 mg/m2 of NPLD plus standard bleomycin, vinblastine and dacarbazine for two cycles (followed by four cycles with NPLD de-escalated at 25 mg/m2 ). Patients underwent R-COMP-DI and MBVD-DI with a median dose intensity of 91% and 94% respectively. At interim-FDG-PET, 72/81 patients (one failed to undergo interim-FDG-PET due to early death) had a Deauville score of ≤3. At end of treatment, 90% of patients reached complete responses. In all, 20 patients had Grade ≥3 adverse events, and four of them required hospitalisation. At a median 21-months of follow-up, the progression-free survival of the entire population was 77.3% (95% confidence interval 68%-88%). Our data suggest that the NPLD supercharge-driven strategy in high-risk DLBCL/c-HL may be a promising option to test in phase III trials, for improving negative interim-FDG-PET cases incidence.
引用
- Picardi M, Giordano C, Pugliese N, et al. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol. 2022. PMID: 35819919. doi:10.1111/bjh.18348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。